Excessive levels of platelet-derived EVs have been implicated in many diseases and AEMD is developing a pipeline of indications for the device leveraging highly cost efficient steps.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
Excessive levels of platelet-derived EVs have been implicated in many diseases and AEMD is developing a pipeline of indications for the device leveraging highly cost efficient steps.